Developer docs
API playgroundTry for free, no card

Search company profiles

PledPharma

Full company profile

uuid003h7sx

Namestring
PledPharma
Websiteurl
pledpharma.se
Company typeenum
Private
Founded yearint
2006
Descriptiontext

PledPharma is identified in the input dataset by company name and a Swedish top-level domain (pledpharma.se), which suggests Sweden-domiciled operations. The "Pharma" element of the name is consistent with a pharmaceutical-sector business, but the provided source content does not specify the company's therapeutic area, pipeline assets, development stage, or commercial focus. No product overview, core technology description, proprietary features, customer segments, partnerships, or distribution channels are present in the input.

The available data is effectively empty across all functional dimensions: headcount is unpopulated, revenue and revenue model are unreported, pricing details are explicitly marked as not available, no office locations are listed, no select customers are named, no value proposition differentiators are provided, and no marketing or distribution channels are documented. The structured corporate fields — founded year, legal name, company type, operating status, ownership, subsidiaries, and parent company — are all blank or explicitly marked as undeterminable. The single available source ID notes that the corporate website displayed a verification/loading screen rather than substantive content, which accounts for the absence of first-party material.

As a result, this assessment explicitly flags a comprehensive data gap rather than inferring product, pipeline, customer, or commercial detail. Any strategic, competitive, or financial conclusions in the sections that follow are constrained by the absence of observable evidence, and the company description is intentionally narrow to avoid fabrication beyond what the.se domain and the "Pharma" naming element directly support.

Short descriptiontext

PledPharma is a Sweden-domiciled (based on its .se web domain) pharmaceutical-sector entity. No product, pipeline, customer, revenue, or operational data was available in the provided source content; the corporate website returned a verification/loading screen at the time of capture.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersStockholm, Sweden
HQ citystring
Stockholm
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
pharmaceutical development, clinical stage therapeutics, drug development pipeline, specialty pharmaceuticals, biopharmaceutical research
Industry1 code
PRIMARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Pharmaceuticals
Social media profiles2 records
Cost components1 value
Others
Offering typeServices
Services
Core offering1 text field

The provided source content for PledPharma contains no substantive information about the company's products or services. The source page at http://pledpharma.se/ displayed only a verification/loading screen ("One moment, please... Loader. Please wait while your request is being verified...") and no product, service, or offering details were captured.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1No products or services available
CategoryNo product or service category information is available from the provided source content.
Description

No product or service information is available from the provided source content for PledPharma. The products_and_services field in the source metadata is empty, and the source page at http://pledpharma.se/ displayed only a verification/loading screen.

No data
Peers1 record
TypeRegional player
Description

Solasia Pharma K.K. is a Japan-based specialty pharmaceutical company focused on oncology supportive care that acquired PledPharma in 2020, gaining direct exposure to PledPharma's lead asset (PledOx/Calmangafodipir). Therapeutic-area focus and small-cap clinical-stage scale are aligned; geography (Japan vs. Sweden) keeps it from a direct head-to-head.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses2 records

Each record includes

Headline, Details, Source

Key risks2 records

Each record includes

Headline, Details, Source

Key highlights1 record

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PledPharma

Pharmaceuticalspledpharma.se

PledPharma is a Sweden-domiciled (based on its .se web domain) pharmaceutical-sector entity. No product, pipeline, customer, revenue, or operational data was available in the provided source content; the corporate website returned a verification/loading screen at the time of capture.

What PledPharma does

PledPharma is identified in the input dataset by company name and a Swedish top-level domain (pledpharma.se), which suggests Sweden-domiciled operations. The "Pharma" element of the name is consistent with a pharmaceutical-sector business, but the provided source content does not specify the company's therapeutic area, pipeline assets, development stage, or commercial focus. No product overview, core technology description, proprietary features, customer segments, partnerships, or distribution channels are present in the input.

The available data is effectively empty across all functional dimensions: headcount is unpopulated, revenue and revenue model are unreported, pricing details are explicitly marked as not available, no office locations are listed, no select customers are named, no value proposition differentiators are provided, and no marketing or distribution channels are documented. The structured corporate fields — founded year, legal name, company type, operating status, ownership, subsidiaries, and parent company — are all blank or explicitly marked as undeterminable. The single available source ID notes that the corporate website displayed a verification/loading screen rather than substantive content, which accounts for the absence of first-party material.

As a result, this assessment explicitly flags a comprehensive data gap rather than inferring product, pipeline, customer, or commercial detail. Any strategic, competitive, or financial conclusions in the sections that follow are constrained by the absence of observable evidence, and the company description is intentionally narrow to avoid fabrication beyond what the.se domain and the "Pharma" naming element directly support.

PledPharma firmographics

Firmographics
Name
PledPharma
Website
https://pledpharma.se
Company type
Private
Founded year
2006
Headcount range
1–10 employees
Short description
PledPharma is a Sweden-domiciled (based on its .se web domain) pharmaceutical-sector entity. No product, pipeline, customer, revenue, or operational data was available in the provided source content; the corporate website returned a verification/loading screen at the time of capture.
Ownership category
akta.pro rank

PledPharma industry classification

Industry
Product category
Pharmaceuticals
NAICS
Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Pharmaceutical development
  • Clinical stage therapeutics
  • Drug development pipeline
  • Specialty pharmaceuticals
  • Biopharmaceutical research

Where PledPharma is headquartered

Location

Headquarters

HQ city
Stockholm
HQ country
Sweden
HQ region
Europe

Markets served

PledPharma product offering

Product offering

Core offering

The provided source content for PledPharma contains no substantive information about the company's products or services. The source page at http://pledpharma.se/ displayed only a verification/loading screen ("One moment, please... Loader. Please wait while your request is being verified...") and no product, service, or offering details were captured.

Differentiator

Problem solved

Functional benefit

Products and services

  • No products or services available No product or service information is available from the provided source content for PledPharma. The products_and_services field in the source metadata is empty, and the source page at http://pledpharma.se/ displayed only a verification/loading screen.

Companies that use PledPharma

Customer profile

Ideal customer profiles1 record

PledPharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

PledPharma competitors and assessment

Company assessment

Regional players

  • Solasia Pharma K.K. Solasia Pharma K.K. is a Japan-based specialty pharmaceutical company focused on oncology supportive care that acquired PledPharma in 2020, gaining direct exposure to PledPharma's lead asset (PledOx/Calmangafodipir). Therapeutic-area focus and small-cap clinical-stage scale are aligned; geography (Japan vs. Sweden) keeps it from a direct head-to-head.

Market position

Strengths1 record

Weaknesses2 records

Key risks2 records

Key highlights1 record

Customer concentration

PledPharma social profiles

Digital presence

PledPharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PledPharma leadership team

Management profile

Number of profiles

PledPharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PledPharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PledPharma

What does PledPharma do?

The provided source content for PledPharma contains no substantive information about the company's products or services. The source page at http://pledpharma.se/ displayed only a verification/loading screen ("One moment, please... Loader. Please wait while your request is being verified...") and no product, service, or offering details were captured.

When was PledPharma founded?

PledPharma was founded in 2006. It employs 1 to 10 people.

Where is PledPharma based?

PledPharma is headquartered in Stockholm, Sweden, in the Europe region.

Who are PledPharma's main competitors?

Solasia Pharma K.K. is listed as a regional player.

Does PledPharma have an API?

No public API is recorded for PledPharma.

What industry is PledPharma in?

PledPharma's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireAladote®’s data has been selected for presentation at The International Liver CongressPledPharma announced its abstract on Aladote's Phase Ib/IIa proof-of-principle study was selected for oral presentation at EASL ILC 2019 in Vienna. The study, led by Dr. James Dear, evaluated Aladote for paracetamol overdose, with the company citing unmet clinical need. The presentation is scheduled for April 10-14, 2019.GlobeNewswirePledPharma presents PledOx®’s phase III program at the Gastrointestinal (GI) Cancers SymposiumPledPharma announced its global phase III program POLAR for PledOx® was accepted for a poster presentation at the GI Cancers Symposium in San Francisco. The presentation covers the use of Calmangafodipir to prevent chemotherapy-induced peripheral neuropathy, with a Phase IIb trial showing a 38% effect on sensory nerve damage and 77% on patient-reported neuropathy.GlobeNewswireFirst Asian patient has been included in the global Phase III program for PledOx® and will trigger a milestone payment of 600 MJPY (c.49 MSEK) to PledPharmaPledPharma and Solasia Pharma announced the first Asian patient was included in the global Phase III program for PledOx in Japan, triggering a 600 MJPY milestone payment. The program includes 700 colorectal cancer patients across Europe, Asia, and the US, with top-line results expected in the second half of 2020.GlobeNewswirePledPharma applies for an Orphan Drug Designation (ODD) in the US for AladotePledPharma filed an Orphan Drug Designation application with the US FDA for Aladote, a drug to reduce liver injury from paracetamol overdose. The company expects an FDA response in the first half of 2019, citing potential cost savings and seven years of market exclusivity.GlobeNewswirePledPharma presents results from study on drug candidate Aladote® for paracetamol poisoning at a global toxicology conferencePledPharma announced its Aladote Phase Ib/IIa study results were accepted for a poster presentation at the Society of Toxicology meeting in March 2019. The proof-of-principle study showed Aladote is safe with NAC and reduces liver damage in paracetamol poisoning patients. The company is preparing an orphan drug application to the FDA.GlobeNewswireThe first patient included in PledPharma’s global Phase III program for PledOx®PledPharma announced the first patient enrolled in its global Phase III program for PledOx, a drug to prevent chemotherapy-induced nerve damage in colorectal cancer. The program includes 700 patients across two studies, POLAR-M and POLAR-A, with recruitment expected to take 10-12 months.GlobeNewswireNomination Committee appointed for the 2019 Annual General Meeting in PledPharmaPledPharma appointed a Nomination Committee for its May 7, 2019 Annual General Meeting, with members from four largest shareholders representing about 38% of voting rights. The committee will propose board and auditor appointments, and its chairman is Staffan Persson.GlobeNewswireStudy drug for the PledOx® global phase III programPledPharma announced that its PledOx study drug for the phase III program has been produced and delivered. Dosing of the first patient is expected in Q4 2018, pending health authority approvals. The drug aims to reduce chemotherapy-induced peripheral neuropathy, with a phase IIb trial showing a 38% lower risk of sensory nerve damage.GlobeNewswireDelivery of study drug to the PledOx® phase III program is expected in SeptemberPledPharma announced that delivery of PledOx study drug for its phase III program is expected in September 2018, with first-patient dosing planned for the fourth quarter. The company expects top-line results in the second half of 2020. The phase III program includes two trials, POLAR-M and POLAR-A, for colorectal cancer patients.GlobeNewswirePledPharma establishes a Scientific Advisory Board for the continued clinical development of Aladote®PledPharma announced a Scientific Advisory Board to guide the clinical development of Aladote, a drug candidate to prevent acute liver failure from paracetamol overdose. The board includes experts in toxicology and emergency medicine, aiming to optimize the drug's potential and market approval. A proof-of-principle study in patients with paracetamol poisoning is ongoing.